CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
CureVac has announced its upcoming presentations at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting in Houston from November 8-10, 2024. The company will showcase extended preliminary immunogenicity results from their Phase 1 CVGBM cancer vaccine study in glioblastoma patients.
Building on previous results presented at ESMO Congress, the study demonstrated that CVGBM monotherapy successfully induced cancer antigen-specific T-cell responses in 77% of evaluable patients, with 84% being de novo responses. Three poster presentations are scheduled, covering topics including preliminary immunogenicity results from the CVGBM trial, mRNA vaccination's enhancement of TCRtg T cell therapy efficacy, and T cell receptor identification for TP53 frameshift.
CureVac ha annunciato le sue prossime presentazioni al 39° Congresso Annuale della Società per l'Immunoterapia del Cancro (SITC) che si terrà ad Houston dal 8 al 10 novembre 2024. L'azienda presenterà i risultati preliminari estesi sull'immunogenicità del loro studio di fase 1 CVGBM sul vaccino contro il cancro nei pazienti affetti da glioblastoma.
Basandosi sui risultati precedentemente presentati al Congresso ESMO, lo studio ha dimostrato che la monoterapia CVGBM ha indotto con successo risposte specifiche delle cellule T agli antigeni tumorali nel 77% dei pazienti valutabili, con l'84% di queste che rappresentano risposte de novo. Sono in programma tre presentazioni poster, che tratteranno temi tra cui i risultati preliminari sull'immunogenicità del trial di CVGBM, il miglioramento dell'efficacia della terapia con cellule T TCRtg grazie alla vaccinazione mRNA, e l'identificazione dei recettori delle cellule T per il frameshift TP53.
CureVac ha anunciado sus próximas presentaciones en el 39° Congreso Anual de la Sociedad para la Inmunoterapia del Cáncer (SITC) en Houston, del 8 al 10 de noviembre de 2024. La empresa mostrará resultados preliminares ampliados sobre la inmunogenicidad de su estudio de fase 1 CVGBM sobre la vacuna contra el cáncer en pacientes con glioblastoma.
Basándose en los resultados presentados anteriormente en el Congreso ESMO, el estudio demostró que la monoterapia CVGBM indujo con éxito respuestas de células T específicas para antígenos del cáncer en el 77% de los pacientes evaluables, con un 84% de respuestas de novo. Se programaron tres presentaciones en cartel, que abarcarán temas como los resultados preliminares de inmunogenicidad del ensayo de CVGBM, la mejora de la eficacia de la terapia con células T TCRtg mediante la vacunación con mRNA, y la identificación de receptores de células T para el desplazamiento de marco TP53.
CureVac는 2024년 11월 8일부터 10일까지 휴스턴에서 열리는 암 면역요법 학회(SITC) 제39회 연례 회의에서 발표할 예정이라고 발표했습니다. 이 회사는 교모세포종 환자를 대상으로 한 1상 CVGBM 암 백신 연구의 연장된 예비 면역원성 결과를 선보일 것입니다.
ESMO Congress에서 발표된 이전 결과를 바탕으로, 이 연구는 CVGBM 단독 치료가 평가 가능한 환자 중 77%에서 암 항원 특이적 T세포 반응을 성공적으로 유도했으며, 이 중 84%가 de novo 반응이었다고 보여주었습니다. 세 개의 포스터 발표가 예정되어 있으며, 여기에서는 CVGBM 임상 시험의 예비 면역원성 결과, mRNA 백신이 TCRtg T 세포 요법의 효능을 향상시키는 방법, TP53 프레임쉬프트에 대한 T 세포 수용체 식별 등을 다룰 것입니다.
CureVac a annoncé ses prochaines présentations lors de la 39ème Réunion Annuelle de la Société pour l'Immunothérapie du Cancer (SITC) à Houston, du 8 au 10 novembre 2024. L'entreprise présentera des résultats préliminaires étendus sur l'immunogénicité de son étude de phase 1 CVGBM sur le vaccin contre le cancer chez les patients atteints de glioblastome.
S'appuyant sur des résultats précédemment présentés au Congrès ESMO, l'étude a démontré que la monothérapie CVGBM a induit avec succès des réponses des cellules T spécifiques aux antigènes tumoraux chez 77% des patients évaluables, dont 84% étaient des réponses de novo. Trois présentations par poster sont prévues, abordant des sujets tels que les résultats préliminaires d'immunogénicité de l'essai CVGBM, l'amélioration de l'efficacité de la thérapie par cellules T TCRtg via la vaccination à ARN messager, et l'identification des récepteurs des cellules T pour le déplacement de cadre TP53.
CureVac hat seine bevorstehenden Präsentationen auf dem 39. Jahrestreffen der Gesellschaft für Immuntherapie des Krebses (SITC) in Houston vom 8. bis 10. November 2024 angekündigt. Das Unternehmen wird erweiterte vorläufige Ergebnisse zur Immunogenität seiner Phase-1-Studie CVGBM Krebsimpfstoffstudie bei Glioblastom-Patienten präsentieren.
Aufbauend auf früheren Ergebnissen, die beim ESMO-Kongress präsentiert wurden, zeigte die Studie, dass die CVGBM Monotherapie erfolgreich Tumor-Antigen-spezifische T-Zell-Antworten bei 77% der bewertbaren Patienten induzierte, wobei 84% de novo Antworten waren. Drei Poster-Präsentationen sind geplant, die Themen wie vorläufige Immunogenitätsergebnisse der CVGBM-Studie, die Verbesserung der Wirksamkeit der TCRtg-T-Zell-Therapie durch mRNA-Impfung und die Identifizierung von T-Zell-Rezeptoren für TP53-Rahmenverschiebung abdecken.
- None.
- None.
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / October 28, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced poster presentations at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, taking place November 8-10 in Houston, USA.
CureVac will present, among other data, extended preliminary immunogenicity results from Part A of the dose escalation phase of its ongoing Phase 1 CVGBM cancer vaccine study in patients with resected glioblastoma. The presentation will expand on safety, tolerability and immunogenicity results of the CVGBM trial presented last month at the European Society for Medical Oncology (ESMO) Congress, which demonstrated treatment with CVGBM monotherapy successfully induced cancer antigen-specific T-cell responses in
Details on all poster presentations are below:
Abstract: 697
Title: Preliminary immunogenicity results from the dose escalation phase of a first-in-human study of the mRNA-based cancer vaccine CVGBM in patients with newly diagnosed MGMT-unmethylated glioblastoma
Session type: Poster Presentation
Date: November 8
Presenting Author: Sven Koch, Ph.D., Director Immuno-Monitoring, CureVac SE
Abstract: 380
Title: mRNA vaccination enhances TCRtg T cell therapy efficacy in solid tumors
Session type: Poster Presentation
Date: November 9
Presenting Author: Dr. Johannes Lutz, Director Pre-Clinical Development, CureVac SE
Abstract: 370
Title: Identification and validation of a T cell receptor recognizing shared HLA-A02:01 presented epitope from TP53 frameshift
Session type: Poster Presentation
Date: November 9
Presenting Author: Katka Franke, Ph.D., Pharm.D., Director Oncology Antigen Discovery and Validation, CureVac Netherlands B.V.
About CureVac
CureVac (Nasdaq:CVAC) is a pioneering multinational biotech company founded in 2000 to advance the field of messenger RNA (mRNA) technology for application in human medicine. In more than two decades of developing, optimizing, and manufacturing this versatile biological molecule for medical purposes, CureVac has introduced and refined key underlying technologies that were essential to the production of mRNA vaccines against COVID-19, and is currently laying the groundwork for application of mRNA in new therapeutic areas of major unmet need. CureVac is leveraging mRNA technology, combined with advanced omics and computational tools, to design and develop off-the-shelf and personalized cancer vaccine product candidates. It also develops programs in prophylactic vaccines and in treatments that enable the human body to produce its own therapeutic proteins. Headquartered in Tübingen, Germany, CureVac also operates sites in the Netherlands, Belgium, Switzerland, and the U.S. Further information can be found at www.curevac.com.
CureVac Media and Investor Relations Contact
Dr. Sarah Fakih, Vice President Corporate Communications and Investor Relations
CureVac, Tübingen, Germany
T: +49 7071 9883-1298
M: +49 160 90 496949
sarah.fakih@curevac.com
Forward-Looking Statements CureVac
This press release contains statements that constitute "forward looking statements" as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the opinions, expectations, beliefs, plans, objectives, assumptions or projections of CureVac N.V. and/or its wholly owned subsidiaries CureVac SE, CureVac Manufacturing GmbH, CureVac Inc., CureVac Swiss AG, CureVac Corporate Services GmbH, CureVac Belgium SA and CureVac Netherlands B.V. (the "company") regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of the potential efficacy of the company's vaccine and treatment candidates and the company's strategies, financing plans, cash runway expectations, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as "anticipate," "intend," "believe," "estimate," "plan," "seek," "project," or "expect," "may," "will," "would," "could," "potential," "intend," or "should," the negative of these terms or similar expressions. Forward-looking statements are based on management's current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of the company's performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, ability to obtain funding, ability to conduct current and future preclinical studies and clinical trials, the timing, expense and uncertainty of regulatory approval, reliance on third parties and collaboration partners, ability to commercialize products, ability to manufacture any products, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in the company's industry, the effects of the COVID-19 pandemic on the company's business and results of operations, ability to manage growth, reliance on key personnel, reliance on intellectual property protection, ability to provide for patient safety, fluctuations of operating results due to the effect of exchange rates, delays in litigation proceedings, different judicial outcomes or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company's control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this press release are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.
For further information, please reference the company's reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.
SOURCE: CureVac
View the original press release on accesswire.com
FAQ
What are the key findings of CureVac's (CVAC) CVGBM cancer vaccine study presented at SITC 2024?
When and where is CureVac (CVAC) presenting at the SITC Annual Meeting 2024?
How many poster presentations will CureVac (CVAC) deliver at SITC 2024?
What type of cancer does CureVac's (CVAC) CVGBM vaccine target?
